RVTY · Industrials
REVVITY, INC.
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-08-07
- DividendsImportance 10 · Surprise 6Revvity reaffirmed its dividend following the second-quarter 2026 results. The dividend reaffirmation occurred alongside raised full-year revenue guidance of $2.83 billion-$2.86 billion. The company’s capital…
News · 2026-08-06
- Operating Cash Flow TrendsImportance 20 · Surprise 24Revvity demonstrated strong cash flow in the second quarter of 2026. The company made progress on deleveraging during the quarter. Revvity also accelerated integration of ACD/Labs, which was identified as an…
News · 2026-08-05
- Market Demand TrendsImportance 36 · Surprise 40Revvity reported stronger demand for drug-development tools and diagnostic testing products in the second quarter. The Diagnostics segment delivered 11% organic growth, offsetting a decline in the Life Sciences unit.…
8-K · 2026-08-04
- Guidance / OutlookImportance 80 · Surprise 68Revvity raised its full-year 2026 outlook to pro forma revenue of $2.83 billion to $2.86 billion. The company forecasts pro forma organic revenue growth of 4% to 5% and pro forma adjusted EPS of $5.30 to $5.40. The…
- Headcount / RestructuringImportance 71 · Surprise 82Second-quarter restructuring and other charges increased to $35.5 million from $11.2 million, an increase of approximately $24.3 million. The first-half restructuring and other charge was $46.2 million, compared with…
- Acquisition / Partnership / DivestitureImportance 65 · Surprise 60Revvity entered into a definitive agreement to divest its China Immunodiagnostics business, referred to as China IDX. China IDX represented approximately 6% of Revvity’s total fiscal 2025 revenue, implying a business…
- Segment Revenue TrendsImportance 54 · Surprise 40Diagnostics revenue increased to $371 million from $354 million, representing 12% pro forma growth and 11% pro forma organic growth year over year. Life Sciences revenue declined to $359 million from $366 million, with…
- Revenue Performance and MixImportance 49 · Surprise 32Second-quarter 2026 reported revenue increased to $730 million from $720 million year over year, while pro forma revenue rose 4% to $711 million from $681 million. Life Sciences revenue declined 2% pro forma and 3%…
- Market Demand TrendsImportance 49 · Surprise 32Revvity reported pro forma revenue of $711 million in the second quarter, up 4% year over year, with pro forma organic revenue growth of 3%. Management cited increased demand across its customer base and momentum in…
- Operating Expense TrendsImportance 48 · Surprise 22Second-quarter reported SG&A expense increased to $279 million from $249 million, a 12% year-over-year increase, while pro forma SG&A rose to $266 million from $236 million. Reported research and development expense…
- Liquidity and Debt PositionImportance 47 · Surprise 22Cash and cash equivalents increased to $1.023 billion at July 5, 2026, from $920 million at December 28, 2025. Current assets totaled $2.298 billion, compared with $2.240 billion at year-end 2025, while total…
- Capital ExpendituresImportance 39 · Surprise 38Revvity spent $11.1 million on capital expenditures in the second quarter of 2026, compared with $18.9 million in the prior-year quarter. First-half capital expenditures totaled $30.8 million, down from $34.9 million…
- Operating Income and MarginsImportance 38 · Surprise 40Reported second-quarter GAAP operating income declined to $89 million from $91 million, and GAAP operating margin decreased to 12.2% from 12.6%. Pro forma operating income increased to $94 million from $85 million,…
- Capital Return ProgramImportance 38 · Surprise 46Revvity repurchased $16.0 million of common stock during the second quarter of 2026, compared with $293.9 million in the second quarter of 2025. First-half share repurchases totaled $102.5 million, down from $447.5…
- Income Tax Rate ChangesImportance 29 · Surprise 22Second-quarter reported income before taxes declined to $63.5 million from $68.7 million, while the income-tax provision decreased to $10.1 million from $13.4 million. The implied reported tax rate fell to…
News · 2026-08-04
- Acquisition / Partnership / DivestitureImportance 65 · Surprise 60Revvity entered a definitive agreement to divest its China Immunodiagnostics business. The business represented approximately 6% of fiscal 2025 revenue, and the transaction is expected to close by the end of 2027.…
- Guidance / OutlookImportance 57 · Surprise 60Revvity raised its full-year 2026 revenue guidance to $2.83-$2.86 billion and pro forma adjusted EPS guidance to $5.30-$5.40. Management attributed the improved outlook to stronger diagnostics demand, increased demand…
- AI Drug Discovery DemandImportance 31 · Surprise 42Revvity is seeing increasing orders tied to AI-driven drug-discovery platforms. The demand supports its life sciences tools and high-content screening offerings used by pharmaceutical and biotechnology researchers.…
- Operating Margin DriversImportance 28 · Surprise 42Revvity reported wider margins in the second quarter of 2026, supported by organic growth in Diagnostics and increased demand for higher-margin products and software. One-time tariff refunds and tax timing contributed…
- Tariff Refund ApplicationsImportance 28 · Surprise 42Revvity said recent tariff refunds supported its improved 2026 outlook and provided funds for additional growth investments. Third-party reporting indicated that a portion of second-quarter EPS upside came from…
- Revenue Performance and MixImportance 25 · Surprise 32Revvity reported second-quarter 2026 revenue of $729.69 million, up from $720.28 million a year earlier, representing approximately 1.3% YoY growth. The Diagnostics segment delivered 11% organic growth and offset a…